Atossa Therapeutics (ATOS) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 09, 2018
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	1,488,039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		5,646,552
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 12,935,587	$ 7,217,469
Restricted cash	55,000	55,000
Prepaid expenses	290,331	250,944
Research and development tax rebate receivable	480,495	358,277
Other current assets	161,530	16,344
Total current assets	13,922,943	7,898,034
Furniture and equipment, net	57,804	11,467
Intangible assets, net	55,107	75,686
Other assets	88,518	178,907
Total Assets	14,124,372	8,164,094
Current liabilities
Accounts payable	550,704	334,901
Accrued expenses	51,673	90,105
Payroll liabilities	706,150	784,867
Stock-based compensation liability	2,180,659
Other current liabilities	66,077	15,534
Total Current Liabilities	3,555,263	1,225,407
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of September 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 3,517 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	4
Additional paid-in capital- Series B convertible preferred stock	3,516,996
Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,523,255 and 2,651,952 shares issued and outstanding, as of September 30, 2018 and December 31, 2017, respectively	994,175	477,342
Additional paid-in capital	80,811,088	71,887,674
Accumulated deficit	(74,753,154)	(65,426,329)
Total Stockholders' Equity	10,569,109	6,938,687
Total Liabilities and Stockholders' Equity	$ 14,124,372	$ 8,164,094

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	5,523,255	2,651,952
Common stock, outstanding (in shares)	5,523,255	2,651,952
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	4,000	4,000
Preferred stock, outstanding (in shares)	0	0
Preferred stock, issued (in shares)	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	25,000	0
Preferred stock, outstanding (in shares)	3,517	0
Preferred stock, issued (in shares)	3,517	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses
Research and development	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
General and administrative	1,888,119	1,313,477	5,966,504	3,544,935
Total operating expenses	3,309,970	2,055,927	9,327,067	5,655,781
Operating loss	(3,309,970)	(2,055,927)	(9,327,067)	(5,655,781)
Change in fair value of common stock warrants		(128,300)		(280,747)
Warrant financing expense				(192,817)
Other income (expense)	104	(283)	242	(208)
Loss before income taxes	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Income taxes
Net loss	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Deemed dividend attributable to preferred stock			(11,479,308)	(2,568,132)
Net loss applicable to common shareholders	$ (3,309,866)	$ (2,184,510)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (2.11)	$ (5.71)	$ (13.23)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492	1,034,262	3,645,682	657,184

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Preferred Stock [Member]	Additional Paid in Capital, Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid in Capital, Common Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017			2,651,952
Balance at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449 (in shares)	13,624
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449	$ 14	6,926,778		5,363,759		12,290,551
Allocation of Series B convertible preferred stock proceeds to beneficial conversion feature		(4,782,100)		4,782,100
Deemed Dividend on Series B convertible preferred stock		11,479,308		(11,479,308)
Conversion of Series B convertible preferred stock to common stock (in shares)	(10,107)		2,871,303
Conversion of Series B convertible preferred stock to common stock	$ (10)	(10,106,990)	$ 516,833	9,590,167
Amortization of commitment shares				(59,556)		(59,556)
Compensation cost for stock options granted to executives and employees				726,252		726,252
Net loss					(9,326,825)	(9,326,825)
Balance (in shares) at Sep. 30, 2018	3,517		5,523,255
Balance at Sep. 30, 2018	$ 4	$ 3,516,996	$ 994,175	$ 80,811,088	$ (74,753,154)	$ 10,569,109

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2018USD ($)
Payments of Class A units issuance costs	$ 1,333,449

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,326,825)	$ (6,129,553)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	726,252	560,369
Loss on disposal of assets		17,695
Depreciation and amortization	28,690	102,074
Change in fair value of common stock warrants		280,747
Change in stock-based compensation liability	2,180,659
Warrant financing expense		192,817
Changes in operating assets and liabilities:
Prepaid expenses	(39,387)	14,195
Research and development tax rebate receivable	(122,218)
Accounts payable	215,803	126,079
Payroll liabilities	(78,717)	(142,312)
Accrued expenses	(38,432)	33,578
Other current liabilities	50,543	7,212
Net cash used in operating activities	(6,517,985)	(4,911,268)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture, fixtures and equipment	(54,448)
Net cash used in investing activities	(54,448)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants		745,333
Net cash provided by financing activities	12,290,551	4,616,969
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	5,718,118	(294,299)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	7,272,469	3,082,962
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	12,990,587	2,788,663
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of warrant liability upon exercise of common stock warrants		1,893,160
Amount receivable for warrant exercise		3,900
Allocation of Class A and Class B Unit proceeds to warrant liability		1,612,413
Amortization of commitment shares issued for shares distributed for capital contribution	59,556	59,558
Units Consisting of Series B Convertible Preferred Stock and Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed for issuance of Units, net of issuance costs	12,290,551
Class A and Class B Units [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed for issuance of Units, net of issuance costs		3,871,636
Other Assets 1 [Member]
Changes in operating assets and liabilities:
Other assets	$ (114,353)	$ 25,831

Note 1 - Nature of Operations

Note 1 - Nature of Operations	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 December 31.

Note 2 - Going Concern

Note 2 - Going Concern	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine September 30, 2018, $9.3 $6.5 September 30, 2018, $12.9 $10.4 not no not Management’s plan to continue as a going concern includes obtaining additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans. As of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for the next 9 15 The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine September 30, 2018 not may December 31, 2018. On April 20, 2018, 1 12 12 one $0.18 not April 20, 2018. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Issued Accounting Pronouncements: In February 2016, No. 2016 02, Lease Accounting Topic 842. 12 12 not 12 may not 2019 not No. 2016 02 2016 02 not 11. In November 2016, No. 2016 18, Statement of Cash Flows No. 2016 18 January 1, 2018 2017 three nine September 30, 2018 September 30, 2017, $55,000 no In July 2017, 2017 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception not no no 260 December 15, 2018. No. 2017 11 January 1, 2018. not not In June 2018, 2018 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. 718 718 718 not 606, Revenue from Contracts with Customers December 15, 2018, No. 2018 17 April 1, 2018 not

Note 4 - Prepaid Expenses

Note 4 - Prepaid Expenses	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 4: Prepaid expenses consisted of the following: September 30, December 31, 2018 2017 Prepaid insurance $ 46,618 $ 125,056 Retainer and security deposits 16,718 14,218 Professional services 93,557 97,788 Prepaid research and development 104,299 Financial exchange fees 13,750 Other 15,389 13,882 $ 290,331 $ 250,944

Note 5 - Research and Developme

Note 5 - Research and Development Tax Rebate Receivable	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 5: On May 23, 2017 1 2 $0.435 nine September 30, 2018, $764,000 $333,000 nine September 30, 2018. September 30, 2018, $481,000 $148,000 December 31, 2017.

Note 6 - Payroll Liabilities

Note 6 - Payroll Liabilities	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 6: Payroll liabilities consisted of the following: September 30, December 31, Accrued bonus payable $ 480,917 $ 566,000 Accrued vacation 156,775 147,861 Accrued payroll liabilities 68,458 71,006 Total payroll liabilities $ 706,150 $ 784,867

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7: The Company is authorized to issue a total of 185,000,000 175,000,000 $0.18 10,000,000 $0.001 750,000 $0.001 4,000 $0.001 25,000 $0.001 No no September 30, 2018. On May 19, 2014, May 26, 2014 one one 1 15% 15% 2.0% 2 $15.00, $30.00 2018 On May 9, 2018, 1 25,000 $1,000 one 284 On May 29, 2018, $0.001 25,000 On May 30, 2018, 13,624 13,624 3,869,216 one $4.048 “2018 $12.3 Series B Convertible Preferred Stock The terms and provisions of our Series B convertible preferred stock are: Conversion. first $1,000 $3.52 not 9.99% Fundamental Transactions. 50% 50% Dividends. Voting Rights. no Liquidation Preference . Redemption Rights. not not 2018 The terms and conditions of the warrants included in the 2018 Exercisability four The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction. Cashless Exercise no not may Exercise Price one $4.048 not 4.99% may no 9.99% Transferability may may Exchange Listing not Rights as Stockholder not Redemption Rights may $0.18 $10.56 ten may not first Accounting Treatment The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of $5,363,759, $4,782,100 $11,479,308, $4,782,100, $5,363,759, $1,333,449. $11,479,308 Outstanding Warrants As of September 30, 2018, 4,318,475 Outstanding Warrants to Purchase Shares Exercise Price Expiration Date 2014 public offering 6,483 $540.00 January 29, 2019 Placement agent fees for Company’s offerings 1,106 381.60 – 540.00 November 4, 2018 2017 Warrant B private placement 441,670 3.78 December 22, 2018 2018 Warrants 3,869,216 4.05 May 30, 2022 4,318,475 Conversion of Series B Convertible Preferred Stock During the three nine September 30, 2018, 2,285 10,107 649,156 2,871,303 284

Note 8 - Net Loss Per Share

Note 8 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8: The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic 260, Earnings Per Share The following table summarizes the Company’s calculation of net loss per common share: Three Months Ended September 30, Nine months Ended September 30, 2018 2017 2018 2017 Net Loss Per Share Numerator Net loss $ (3,309,866 ) $ (2,184,510 ) $ (9,326,825 ) $ (6,129,553 ) Deemed dividend attributable to preferred stock (11,479,308 ) (2,568,132 ) Net loss attributable to common shareholders $ (3,309,866 ) $ (2,184,510 ) $ (20,806,133 ) $ (8,697,685 ) Denominator Weighted average common shares outstanding 5,183,492 1,034,262 3,645,682 657,184 Basic and diluted net loss per share $ (0.64 ) $ (2.11 ) $ (5.71 ) $ (13.23 ) The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three nine September 30, 2018 2017 Three Months Ended 30, Nine months Ended September 30, 2018 2017 2018 2017 Options to purchase common stock 783,794 176,502 388,377 100,505 Series A convertible preferred stock 42,480 74,651 Series B convertible preferred stock 1,338,916 751,332 Warrants to purchase common stock 4,716,935 138,365 2,644,946 227,229 Total 6,839,645 357,347 3,784,655 402,385 For the three nine September 30, 2018 2017,

Note 9 - Income Taxes

Note 9 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No September 30, 2018 December 31, 2017

Note 10 - Concentration of Cred

Note 10 - Concentration of Credit Risk	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 10: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. September 30, 2018 December 31, 2017, $12,685,587 $6,967,469

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: Lease Commitments On November 1, 2018, $3,660 22 $80,500. Litigation and Contingencies On October 10, 2013, Cook v. Atossa Genetics, Inc., et al. No. 2:13 01836 November 2012 11 12 2 15, 10 20A 10b 5 November 8, 2012 October 4, 2013, On March 23, 2018, $3.5 July 20, 2018 September 30, 2018. We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 12 - Stock Based Compensat

Note 12 - Stock Based Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 12: Stock Option and Incentive Plan On September 28, 2010, 2010 “2010 may 2010 September 2020. No may 2010 10 5,556 2010 May 18, 2016, 11,111 2010 May 9, 2017, 125,000 2010 April 12, 2018, 500,000 2010 The following table presents the automatic additions to the 2010 2010 January 1, Number of shares 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 18,368 2017 12,623 2018 106,076 Total additional shares 152,031 The Company did not three September 30, 2018 2017. No three nine September 30, 2018. 3,197 2010 September 30, 2018. Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $332,063 $224,254 three September 30, 2018 2017, $726,252 $560,369 nine September 30, 2018 2017, Options issued and outstanding as of September 30, 2018 2010 nine Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2018 172,510 $ 49.27 $ Granted 611,668 2.39 Forfeited (417 ) 5.64 Expired Outstanding as of September 30, 2018 783,761 12.70 9.42 $ Exercisable as of September 30, 2018 199,949 40.62 8.95 $ Vested and expected to vest 783,761 12.70 9.42 $ At September 30, 2018, 583,812 $1,479,610. 1.56 Option Grants Classified as Liabilities (“Liability Grants”) On June 27, 2018, 2,300,000 700,000 2010 2010 The Liability Grants are exercisable for shares of common stock at an exercise price of $2.38 ten may not The Liability Grants are subject to vesting requirements. Twenty- five 50% two 25% September 30 2018, 80% Compensation costs associated with the Liability Grants are initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria will be achieved for options that vest based on performance. Compensation cost is remeasured each period based on the market value of our underlying stock until award vesting or settlement. For the three nine September 30, 2018, $623,496 $2,180,659, The fair value of liability options granted for the nine September 30, 2018 Nine months ended September 30, 2018 Risk free interest rate 2.94 % Expected term (in years) 4.75 Stock price $1.75 Dividend yield % Expected volatility 122.0 %

Note 13 - Restatement to Previo

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Reclassifications [Text Block]	NOTE 13: The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the three six June 30, 2018 10 August 13, 2018 ( 10 May 2018 10 not not three six June 30, 2018 $4,782,100 $11,479,308 not In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Operations for the three six June 30, 2018: For the Three Months Ended For the Six Months Ended Previously Reported Restated Previously Reported Restated Deemed dividend attributable to preferred stock $ (4,782,100 ) $ (11,479,308 ) $ (4,782,100 ) $ (11,479,308 ) Net loss applicable to common stockholders $ (8,924,677 ) $ (15,621,885 ) $ (10,799,059 ) $ (17,496,267 ) Loss per common share -basic and diluted $ (2.90 ) $ (5.08 ) $ (3.77 ) $ (6.11 ) The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Stockholders’ Equity for the six June 30, 2018: Preferred Stock Additional Paid-in Capital Common Stock Additional Paid-in Capital Previously Reported Restated Previously Reported Restated Issuance of Series B convertible preferred stock, net of issuance costs $ 12,290,537 $ 6,926,778 $ 0 $ 5,363,759 Deemed Dividend on Series B convertible preferred stock $ 4,782,100 $ 11,479,308 $ (4,782,100 ) $ (11,479,308 ) Conversion of Series B convertible preferred stock to common stock $ (7,056,421 ) $ (7,821,992 ) $ 6,656,442 $ 7,422,013

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine September 30, 2018 not may December 31, 2018. On April 20, 2018, 1 12 12 one $0.18 not April 20, 2018.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements: In February 2016, No. 2016 02, Lease Accounting Topic 842. 12 12 not 12 may not 2019 not No. 2016 02 2016 02 not 11. In November 2016, No. 2016 18, Statement of Cash Flows No. 2016 18 January 1, 2018 2017 three nine September 30, 2018 September 30, 2017, $55,000 no In July 2017, 2017 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception not no no 260 December 15, 2018. No. 2017 11 January 1, 2018. not not In June 2018, 2018 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. 718 718 718 not 606, Revenue from Contracts with Customers December 15, 2018, No. 2018 17 April 1, 2018 not

Note 4 - Prepaid Expenses (Tabl

Note 4 - Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	September 30, December 31, 2018 2017 Prepaid insurance $ 46,618 $ 125,056 Retainer and security deposits 16,718 14,218 Professional services 93,557 97,788 Prepaid research and development 104,299 Financial exchange fees 13,750 Other 15,389 13,882 $ 290,331 $ 250,944

Note 6 - Payroll Liabilities (T

Note 6 - Payroll Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, Accrued bonus payable $ 480,917 $ 566,000 Accrued vacation 156,775 147,861 Accrued payroll liabilities 68,458 71,006 Total payroll liabilities $ 706,150 $ 784,867

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Warrants to Purchase Shares Exercise Price Expiration Date 2014 public offering 6,483 $540.00 January 29, 2019 Placement agent fees for Company’s offerings 1,106 381.60 – 540.00 November 4, 2018 2017 Warrant B private placement 441,670 3.78 December 22, 2018 2018 Warrants 3,869,216 4.05 May 30, 2022 4,318,475

Note 8 - Net Loss Per Share (Ta

Note 8 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine months Ended September 30, 2018 2017 2018 2017 Net Loss Per Share Numerator Net loss $ (3,309,866 ) $ (2,184,510 ) $ (9,326,825 ) $ (6,129,553 ) Deemed dividend attributable to preferred stock (11,479,308 ) (2,568,132 ) Net loss attributable to common shareholders $ (3,309,866 ) $ (2,184,510 ) $ (20,806,133 ) $ (8,697,685 ) Denominator Weighted average common shares outstanding 5,183,492 1,034,262 3,645,682 657,184 Basic and diluted net loss per share $ (0.64 ) $ (2.11 ) $ (5.71 ) $ (13.23 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended 30, Nine months Ended September 30, 2018 2017 2018 2017 Options to purchase common stock 783,794 176,502 388,377 100,505 Series A convertible preferred stock 42,480 74,651 Series B convertible preferred stock 1,338,916 751,332 Warrants to purchase common stock 4,716,935 138,365 2,644,946 227,229 Total 6,839,645 357,347 3,784,655 402,385

Note 12 - Stock Based Compens_2

Note 12 - Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	January 1, Number of shares 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 18,368 2017 12,623 2018 106,076 Total additional shares 152,031
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2018 172,510 $ 49.27 $ Granted 611,668 2.39 Forfeited (417 ) 5.64 Expired Outstanding as of September 30, 2018 783,761 12.70 9.42 $ Exercisable as of September 30, 2018 199,949 40.62 8.95 $ Vested and expected to vest 783,761 12.70 9.42 $
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine months ended September 30, 2018 Risk free interest rate 2.94 % Expected term (in years) 4.75 Stock price $1.75 Dividend yield % Expected volatility 122.0 %

Note 13 - Restatement to Prev_2

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	For the Three Months Ended For the Six Months Ended Previously Reported Restated Previously Reported Restated Deemed dividend attributable to preferred stock $ (4,782,100 ) $ (11,479,308 ) $ (4,782,100 ) $ (11,479,308 ) Net loss applicable to common stockholders $ (8,924,677 ) $ (15,621,885 ) $ (10,799,059 ) $ (17,496,267 ) Loss per common share -basic and diluted $ (2.90 ) $ (5.08 ) $ (3.77 ) $ (6.11 ) Preferred Stock Additional Paid-in Capital Common Stock Additional Paid-in Capital Previously Reported Restated Previously Reported Restated Issuance of Series B convertible preferred stock, net of issuance costs $ 12,290,537 $ 6,926,778 $ 0 $ 5,363,759 Deemed Dividend on Series B convertible preferred stock $ 4,782,100 $ 11,479,308 $ (4,782,100 ) $ (11,479,308 ) Conversion of Series B convertible preferred stock to common stock $ (7,056,421 ) $ (7,821,992 ) $ 6,656,442 $ 7,422,013

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total	$ (3,309,866)	$ (2,184,510)	$ (9,326,825)	$ (6,129,553)
Net Cash Provided by (Used in) Operating Activities, Total			(6,517,985)	$ (4,911,268)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	12,935,587		12,935,587		$ 7,217,469
Working Capital	$ 10,400,000		$ 10,400,000

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Details Textual)	Apr. 20, 2018	Sep. 30, 2018USD ($)$ / shares	Dec. 31, 2017$ / shares	Sep. 30, 2017USD ($)
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.18	$ 0.18
Restricted Cash and Cash Equivalents, Total | $		$ 55,000		$ 55,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	12

Note 4 - Prepaid Expenses - Sch

Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid insurance	$ 46,618	$ 125,056
Retainer and security deposits	16,718	14,218
Professional services	93,557	97,788
Prepaid research and development	104,299
Financial exchange fees	13,750
Other	15,389	13,882
	$ 290,331	$ 250,944

Note 5 - Research and Develop_2

Note 5 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	May 23, 2017
Research and Development Expense, Total	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
Increase (Decrease) in Research and Development Tax Rebate Receivable			122,218
Research and Development Tax Rebate Receivable	480,495		480,495		$ 358,277
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar						$ 0.435
Research and Development Expense, Total			764,000
Increase (Decrease) in Research and Development Tax Rebate Receivable			333,000
Research and Development Tax Rebate Receivable	$ 481,000		$ 481,000		$ 148,000

Note 6 - Payroll Liabilities -

Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued bonus payable	$ 480,917	$ 566,000
Accrued vacation	156,775	147,861
Accrued payroll liabilities	68,458	71,006
Total payroll liabilities	$ 706,150	$ 784,867

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual)	May 30, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	May 29, 2018$ / shares	May 09, 2018$ / itemshares	Dec. 31, 2017$ / sharesshares	May 19, 2014$ / sharesshares
Number of Shares Authorized to Issue		185,000,000				185,000,000
Common Stock, Shares Authorized		175,000,000				175,000,000				175,000,000
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.18				$ 0.18				$ 0.18
Preferred Stock, Shares Authorized		10,000,000				10,000,000				10,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001				$ 0.001				$ 0.001
Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock											1
Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership											15.00%
Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership											2.00%
Stockholder Rights Agreement, Initial Exercise Price of Each Right | $ / shares											$ 15
Stockholder Rights Agreement, Share Price | $ / shares											$ 30
Class of Warrant or Right, Outstanding		4,318,475				4,318,475
Consummate a Business Combination, Percentage of Acquired Outstanding Shares		50.00%				50.00%
Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power		50.00%				50.00%
Preferred Stock, Deemed Dividend | $			$ 11,479,308		$ 11,479,308	$ 11,479,308	$ 2,568,132
Payments of Stock Issuance Costs | $						$ 1,333,449
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,318,475				4,318,475
Conversion of Stock, Shares Converted		2,285				10,107
The 2018 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.048	$ 4.048				$ 4.048
Warrants and Rights Outstanding, Term		4 years				4 years
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed		4.99%				4.99%
Warrants and Rights Outstanding, Redemption Price | $ / shares		$ 0.18				$ 0.18
Warrants and Rights Outstanding, Redeemable, Volume-weighted-average-price of Our Common Stock | $ / shares		$ 10.56				$ 10.56
The 2018 Subscription Rights Offering [Member]
Number of Units Authorized to Purchase, Maximum									25,000
Purchase Price of Unit | $ / item									1,000
Number of Series B Convertible Preferred Stock and Warrant in Each Unit									1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									284
Number of Units Sold	13,624
Proceeds from Issuance of Stock units | $	$ 12,300,000
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock | $						$ 4,782,100
Preferred Stock, Deemed Dividend | $						11,479,308
Payments of Stock Issuance Costs | $						1,333,449
The 2018 Subscription Rights Offering [Member] | The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding	3,869,216
Warrants Allocated to Common Stock , Net of Issuance Cost | $		$ 5,363,759				$ 5,363,759
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized		750,000				750,000
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001				$ 0.001
Preferred Stock, Shares Issued, Total		0				0
Preferred Stock, Shares Outstanding, Ending Balance		0				0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		4,000				4,000				4,000
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001				$ 0.001				$ 0.001
Preferred Stock, Shares Issued, Total		0				0
Preferred Stock, Shares Outstanding, Ending Balance		0				0				0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		25,000				25,000				0
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001				$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total		3,517				3,517				0
Stated Value per Share | $ / shares		1,000				1,000
Preferred Stock, Convertible, Conversion Price | $ / shares		$ 3.52				$ 3.52
Preferred Stock, Convertible, Ownership Percentage of Company’s Shares Allowed		9.99%				9.99%
Convertible Preferred Stock, Shares Issued upon Conversion		284				284
Preferred Stock, Shares Outstanding, Ending Balance		3,517				3,517				0
Series B Convertible Preferred Stock [Member] | The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624
Common Stock [Member]
Conversion of Stock, Shares Issued		649,156				2,871,303

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Schedule of Warrants (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Class of Warrant or Right, Outstanding (in shares) | shares	4,318,475
The 2014 Public Offering [Member]
Class of Warrant or Right, Outstanding (in shares) | shares	6,483
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 540
Expiration Dates of Class of Warrant or Right	January 29, 2019
Placement Agent Fee [Member]
Class of Warrant or Right, Outstanding (in shares) | shares	1,106
Expiration Dates of Class of Warrant or Right	November 4, 2018
Placement Agent Fee [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 381.60
Placement Agent Fee [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 540
The 2017 Warrant B Private Placement [Member]
Class of Warrant or Right, Outstanding (in shares) | shares	441,670
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 3.78
Expiration Dates of Class of Warrant or Right	December 22, 2018
The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding (in shares) | shares	3,869,216
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 4.05
Expiration Dates of Class of Warrant or Right	May 30, 2022

Note 8 - Net Loss Per Share - S

Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Net loss	$ (3,309,866)		$ (2,184,510)		$ (9,326,825)	$ (6,129,553)
Deemed dividend attributable to preferred stock		$ (11,479,308)		$ (11,479,308)	(11,479,308)	(2,568,132)
Net loss applicable to common stockholders	$ (3,309,866)	$ (15,621,885)	$ (2,184,510)	$ (17,496,267)	$ (20,806,133)	$ (8,697,685)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492		1,034,262		3,645,682	657,184
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (5.08)	$ (2.11)	$ (6.11)	$ (5.71)	$ (13.23)

Note 8 - Net Loss Per Share -_2

Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Number of potential common shares excluded (in shares)	6,839,645	357,347	3,784,655	402,385
Employee Stock Option [Member]
Number of potential common shares excluded (in shares)	783,794	176,502	388,377	100,505
Series A Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)		42,480		74,651
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	1,338,916		751,332
Warrant [Member]
Number of potential common shares excluded (in shares)	4,716,935	138,365	2,644,946	227,229

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued Income Taxes, Total	$ 0	$ 0

Note 10 - Concentration of Cr_2

Note 10 - Concentration of Credit Risk (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Cash, Uninsured Amount	$ 12,685,587	$ 6,967,469

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 01, 2018	Mar. 23, 2018
Loss Contingency, Damages Paid, Value		$ 3,500,000
Subsequent Event [Member]
Operating Lease, Lessee, Monthly Rent Expense	$ 3,660
Lessee, Operating Lease, Term of Contract	1 year 300 days
Operating Leases, Future Minimum Payments Due, Total	$ 80,500

Note 12 - Stock Based Compens_3

Note 12 - Stock Based Compensation (Details Textual) - USD ($)	Jun. 27, 2018	Apr. 12, 2018	May 09, 2017	May 18, 2016	Sep. 28, 2010	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Liability Options [Member]
Allocated Share-based Compensation Expense, Total						$ 623,496		$ 2,180,659
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards Vested						80.00%		80.00%
Liability Options [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Liability Options [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Liability Options [Member] | Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Liability Options [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Liability Options [Member] | Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,300,000
Liability Options [Member] | Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	700,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								611,668
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 2.39
The 2010 Stock Option and Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		500,000	125,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						0		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						3,197		3,197
Allocated Share-based Compensation Expense, Total						$ 332,063	$ 224,254	$ 726,252	$ 560,369
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance						583,812		583,812
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options						$ 1,479,610		$ 1,479,610
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 204 days

Note 12 - Stock Based Compens_4

Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	12 Months Ended							84 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2017
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	106,076	12,623	18,368	5,463	4,128	2,871	2,502	152,031

Note 12 - Stock Based Compens_5

Note 12 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member] - USD ($)	9 Months Ended
	Sep. 30, 2018
Outstanding, shares (in shares)	172,510
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 49.27
Granted, shares (in shares)	611,668
Granted, Weighted average exercise price per share (in dollars per share)	$ 2.39
Forfeited, shares (in shares)	(417)
Forfeited, Weighted average exercise price per share (in dollars per share)	$ 5.64
Expired, shares (in shares)
Expired, Weighted average exercise price per share (in dollars per share)
Outstanding, shares (in shares)	783,761
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 12.70
Outstanding, weighted average contractual life remaining in years (Year)	9 years 153 days
Outstanding, Aggregate intrinsic value
Exercisable, shares (in shares)	199,949
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 40.62
Exercisable, weighted average contractual life remaining in years (Year)	8 years 346 days
Exercisable, Aggregate intrinsic value
Vested and expected to vest, shares (in shares)	783,761
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 12.70
Vested and expected to vest, weighted average contractual life remaining in years (Year)	9 years 153 days
Vested and expected to vest, Aggregate intrinsic value

Note 12 - Stock Based Compens_6

Note 12 - Stock Based Compensation - Valuation Assumptions (Details) - Liability Options [Member]	9 Months Ended
	Sep. 30, 2018$ / shares
Risk free interest rate	2.94%
Expected term (in years) (Year)	4 years 273 days
Stock price (in dollars per share)	$ 1.75
Dividend yield
Expected volatility	122.00%

Note 13 - Restatement to Prev_3

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Preferred Stock, Deemed Dividend		$ 11,479,308		$ 11,479,308	$ 11,479,308	$ 2,568,132
Series B Convertible Preferred Stock [Member]
Deemed Dividend on Series B Convertible Preferred Stock		11,479,308		11,479,308
Previously Reported [Member]
Preferred Stock, Deemed Dividend		4,782,100		4,782,100
Previously Reported [Member] | Series B Convertible Preferred Stock [Member]
Preferred Stock, Deemed Dividend		$ 4,782,100		$ 4,782,100

Note 13 - Restatement to Prev_4

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Deemed dividend attributable to preferred stock		$ (11,479,308)		$ (11,479,308)	$ (11,479,308)	$ (2,568,132)
Net loss applicable to common stockholders	$ (3,309,866)	$ (15,621,885)	$ (2,184,510)	$ (17,496,267)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (5.08)	$ (2.11)	$ (6.11)	$ (5.71)	$ (13.23)
Issuance of Series B convertible preferred stock, net of issuance costs					$ 12,290,551
Deemed Dividend on Series B convertible preferred stock
Conversion of Series B convertible preferred stock to common stock
Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 6,926,778			6,926,778
Deemed Dividend on Series B convertible preferred stock		11,479,308			11,479,308
Conversion of Series B convertible preferred stock to common stock		(7,821,992)			(10,106,990)
Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs				$ 5,363,759	5,363,759
Deemed Dividend on Series B convertible preferred stock				(11,479,308)	(11,479,308)
Conversion of Series B convertible preferred stock to common stock				7,422,013	$ 9,590,167
Previously Reported [Member]
Deemed dividend attributable to preferred stock		(4,782,100)		(4,782,100)
Net loss applicable to common stockholders		$ (8,924,677)		$ (10,799,059)
Loss per common share -basic and diluted (in dollars per share)		$ (2.90)		$ (3.77)
Previously Reported [Member] | Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 12,290,537
Deemed Dividend on Series B convertible preferred stock		4,782,100
Conversion of Series B convertible preferred stock to common stock		$ (7,056,421)
Previously Reported [Member] | Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs				$ 0
Deemed Dividend on Series B convertible preferred stock				(4,782,100)
Conversion of Series B convertible preferred stock to common stock				$ 6,656,442